FDA Approves Sacituzumab Govitecan-hziy for Triple-Negative Breast Cancer

On April 7, 2021 the U.S. Food and Drug Administration (FDA) granted regular approval to sacituzumab govitecan-hziy for patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior systemic therapies, at least one of them for metastatic disease.

Read the FDA announcement.

Read the Gilead Sciences announcement.

Posted 4/8/2021